Virtual Poster Session in NETs From Barcelona - prIME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session in NETs From Barcelona

Practical Application of Key Data Presented During the Annual Neuroendocrine Cancer Meeting in Barcelona

Not a member of My prIME? Join now for instant access.

View abstract presentations and downloadable slides from the 2018 Annual Neuroendocrine Cancer Meeting in Barcelona.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



Release Date

Release Date

Mar 14, 2018

Expiration Date

Mar 14, 2019

Neuroendocrine tumors

Jaume Capdevila, MD, PhD

Abstract #B03: BRAF-V600E driven mutations in grade 3 neuroendocrine carcinomas of colon origin: Results from genomic/epigenomic profilings and patient-derived mouse model

Featured Expert: Jaume Capdevila, MD, PhD

Jaume Capdevila, MD, PhD

Abstract #H03: Prospective, multi-center, open label, phase study II of APOC, a new controlled release 15mg octreotide acetate, for the treatment of advanced NETs

Featured Expert: Jaume Capdevila, MD, PhD

Faidon-Marios Laskaratos, MSc, MRCP

Abstract #H18: Predictors of antiproliferative effect of lanreotide autogel (LA) as first-line therapy for advanced neuroendocrine tumors (NETs)

Featured Expert: Faidon-Marios Laskaratos, MSc, MRCP

Else A. Aalbersberg, MSc

Abstract #K01: Influence of lanreotide on uptake of [68Ga]-DOTATATE in patients with NETs

Featured Expert: Else A. Aalbersberg, MSc

Jonathan Strosberg, MD

Abstract #K22: Overall survival, progression-free survival, and quality of life updates from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors

Featured Expert: Jonathan Strosberg, MD

  • Else A. Aalbersberg, MScThe Netherlands Cancer Institute
    Amsterdam, the Netherlands
  • Jaume Capdevila, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Faidon-Marios Laskaratos, MSc, MRCPRoyal Free Hospital
    London, United Kingdom
  • Jonathan Strosberg, MDMoffitt Cancer Center
    Tampa, Florida, United States

This educational activity is supported by IPSEN.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and Independent Medical Education (IME) performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Disclosure Information


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.